focus -WSS

focus

author：focus 2025-10-01 11:43:49 - browse：13

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Clinical trials giant ICON acquires HumanFirst

WSS

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Change Healthcare cyberattack outage could last weeks

Citing H5N1 threat, CDC urges peak flu monitoring this summer

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Biotech companies concerned about China biosecurity crackdown

As a primary care physician, here's how I hope to partner with AI

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

How one medical school became remarkably diverse

H5N1 bird flu outbreak: Second human case reported, in Michigan

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Hepatitis C has a cure — but many Americans still lack access to it

How to fix the rural physician shortage in the U.S.

Walensky prepares to leave CDC — and Congress — behind

Making the case for fair compensation in clinical trials

George Santos makes 1st court appearance after pleading not guilty to 13 counts

H5N1 bird flu outbreak: Second human case reported, in Michigan

focus

Biogen joins immunology wave with $1.15 billion acquisition of HI

Biogen joins immunology wave with $1.15 billion acquisition of HI

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Congress gives doctors Medicare pay bump

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Flu vaccine offering decent levels of protection this winter, new data show

hotspot

Wikipedia

explore

Wikipedia